Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.

Related Content

Advertising Review In Brief
More Consumers Turn To Pharmacists For OTC Advice – Study
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Pricing Strategy Can Help Brands Regain Share Lost To Private Label – Expert
News In Brief
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"
Perrigo's Potential OTC Product Pipeline
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo Gains Pole Position In Private-Label Allegra Race





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts